Three UK universities have been granted over \u00a31.7m by the Medical Research Council (MRC) to establish a network of lymph node research centres across the UK. The novel LEGACY IIII Network (Lymph nodE single cell Genomics AnCestrY immunity, infection, inflammation and immunisation) will be co-led by the Universities of Oxford, Cardiff and Newcastle and will establish ten specialist lymph node research centres across the country.
The University of Oxford, through its strategic partnership with the Ellison Institute of Technology (EIT), has received research funding of \u00a3118m to launch an ambitious new programme of vaccine research.
His Royal Highness the Duke of Gloucester visited the University of Oxford on Thursday 24th July to tour two of its leading medical research centres: the Clinical BioManufacturing Facility and the laboratories of the Oxford Vaccine Group (OVG) and Pandemic Sciences Institute (PSI), located on the University\u2019s Old Road Campus.
The University of Oxford held a groundbreaking ceremony on Tuesday 24 June to celebrate the start of construction of the Cyrus Poonawalla Vaccines Research Building. The ceremony marks a significant milestone in Oxford\u2019s mission to counter and constrain global health threats.
Last month, Professor Teresa Lambe OBE, the Calleva Head of Vaccine Immunology and Professor of Vaccinology & Immunology at the Oxford Vaccine Group at the University of Oxford, delivered an inspiring speech at the University of Notre Dame\u2019s Graduate School\u2019s annual Commencement Ceremony.
The University of Oxford\u2019s vaccine to protect people from deadly Nipah virus has been granted support from the PRIority MEdicines (PRIME) scheme offered by Europe\u2019s medicines regulator, the European Medicines Agency (EMA). It is the first UK academic institution to be awarded this designation.
The outcome of a trial published in Science Translational Medicine, shows encouraging results for a new vaccine targeting group B meningococcus (MenB), a significant cause of meningococcal disease worldwide, and establishes proof-of-concept in humans that a gene-based vaccine platform can induce protective antibody responses against bacteria.
Results of two parallel studies show that one in four African children hospitalised with malaria and coma have an additional infection, and that giving antibiotics with antimalarials could help reduce death rates of comatose children.
The Oxford Vaccine Group has launched a novel clinical study, BIO-006, to investigate relapsing malaria infections caused by\u202fPlasmodium vivax. This unique parasite can remain dormant in the liver for months or years, reactivating to cause repeated malaria infections.
A new book by Professor Samantha Vanderslott of the University of Oxford, Pro-vax, is set to redefine how we think about vaccination by spotlighting a critical but often-overlooked force: pro-vaccine activism.
The Oxford Vaccine Group has launched a new clinical study, BiVISTA, to evaluate an experimental combination vaccine aimed at preventing enteric fever a disease caused by two different types of Salmonella bacteria, typhoid and paratyphoid.
The Ineos Oxford Institute for antimicrobial research (IOI) has awarded over \u00a32m to six projects across the University of Oxford focused on developing new solutions to tackle antimicrobial resistance (AMR), including one at the Oxford Vaccine Group.
A single dose of typhoid conjugate vaccine (TCV) offers safe, effective protection against typhoid two years after vaccination in all children, and sustained protection for older children at three to five years post immunisation, according to a report by researchers at the Oxford Vaccine Group and icddr,b. But it also shows a decline in protection at the later timepoints among children vaccinated at younger ages.
Parents are being urged to get their children vaccinated as experts launch a campaign to boost uptake in the UK amid rising cases of whooping cough and measles. Researchers at the Oxford Vaccine Group, which is part of the University of Oxford, have developed an animation that, they say, focuses on the \"critical role\" whooping cough jabs play in protecting against infection, which can cause serious complications such as pneumonia.
The Oxford Vaccine Group has released new footage of ground-breaking research aimed at revolutionising vaccine design, particularly for those most vulnerable to diseases like flu and COVID-19.
Professor Teresa Lambe OBE, Calleva Head of Immunology at the Oxford Vaccine Group, and Principal Investigator at the Pandemic Sciences Institute, has been elected a Fellow of the Academy of Medical Sciences, one of the most prestigious awards in the field.
Babies and the most vulnerable are at risk of death if vaccination rates for whooping cough don't increase, according to experts at the University of Oxford.
![\"\"](\"https://www.ovg.ox.ac.uk/news/major-investment-puts-uk-universities-at-the-forefront-of-groundbreaking-lymph-node-research/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n